A Phase II Multicenter Study of Ruxolitinib in Patients With T or NK Cell Lymphoma That Has Either Come Back or Not Responded to Treatment
Phase of Trial: Phase II
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Ruxolitinib (Primary)
- Indications T cell lymphoma
- Focus Therapeutic Use
- 11 Apr 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
- 11 Apr 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
- 29 Nov 2016 New trial record